Spotted a factual error — a wrong number, date, or fact? Tell us and we will check the source.
1. At a Glance – Small Company, Big Confidence
Biopol Chemicals is walking into the market with the confidence of a company that thinks it has cracked specialty chemicals and capital markets in one go. At a pre-IPO market cap of ₹116.70 Cr, the company is asking investors to trust a 2-year-old incorporated entity with a ₹31 Cr fresh capital raise, priced at ₹102–₹108, translating into a post-IPO P/E of ~14.6x.
Revenue for Dec 2025 stands at ₹48.97 Cr, almost equal to FY25 full-year revenue. PAT is ₹6 Cr, margins are expanding, ROE is a juicy 36%, and EBITDA margin has jumped to 18.41%. On paper, this looks like a chemistry topper.
But pause.
Retail investors need ₹2.59 lakh minimum just to apply. This is SME, but with mainboard ego. Is the business genuinely scalable or just well-dressed for the IPO party?
Let’s put the beaker under the microscope.
2. Introduction – When a 2-Year-Old Company Wants ₹31 Crore
Biopol Chemicals was incorporated in 2023, which means it learned to walk yesterday and is now asking public investors to sponsor its gym membership.
The company operates in specialty chemicals, one of the most seductive sectors for Indian investors. Why? Because “specialty” sounds like pricing power, entry barriers, and China+1 fairy tales.
And Biopol knows this.
The numbers show sharp growth, especially in the pre-IPO period, which is exactly when companies suddenly discover operational excellence, margin discipline, and accounting enlightenment.
This doesn’t mean fraud. But it does mean you should read every line twice.
3. Business Model – WTF Do They Even Do?
Biopol Chemicals is a B2B specialty chemical manufacturer supplying chemicals used in:
Textiles
Home care
Agriculture
Industrial applications
Their portfolio includes 66 products, dominated by silicone-based chemicals.
